BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3897478)

  • 1. Source of fibrin/fibrinogen degradation products in the CSF after subarachnoid hemorrhage.
    Vermeulen M; van Vliet HH; Lindsay KW; Hijdra A; van Gijn J
    J Neurosurg; 1985 Oct; 63(4):573-7. PubMed ID: 3897478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring fibrinolytic activity in the cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: a guide to the risk of rebleeding?
    Maurice-Williams RS; Gordon YB; Sykes A
    J Neurol Neurosurg Psychiatry; 1980 Feb; 43(2):175-81. PubMed ID: 7359154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of antifibrinolytic therapy following subarachnoid hemorrhage. The importance of CSF fibrin/fibrinogen degradation products.
    Sawaya R; Sonnino V; McLaurin RL; Perrotta G
    J Neurosurg; 1983 May; 58(5):699-707. PubMed ID: 6834119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation and fibrinolysis in blood and cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: effect of tranexamic acid (AMCA).
    Fodstad H; Nilsson IM
    Acta Neurochir (Wien); 1981; 56(1-2):25-38. PubMed ID: 7195642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage.
    Fodstad H; Pilbrant A; Schannong M; Strömberg S
    Acta Neurochir (Wien); 1981; 58(1-2):1-13. PubMed ID: 7282453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic activity after subarachnoid haemorrhage and the effect of tranexamic acid.
    Tsementzis SA; Honan WP; Nightingale S; Hitchcock ER; Meyer CH
    Acta Neurochir (Wien); 1990; 103(3-4):116-21. PubMed ID: 2205078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of fibrin and fibrinogen degradation products (FDP) in the cerebrospinal fluid of patients with subarachnoid haemorrhage due to ruptured aneurysm. Report of 55 cases.
    Schisano G; Franco A; Nina P; Papa ML; Iannuzzi M; De Biase R; Caldora M
    J Neurosurg Sci; 1994 Jun; 38(2):77-86. PubMed ID: 7891197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tranexamic acid (AMCA) in aneurysmal subarachnoid haemorrhage.
    Fodstad H
    J Clin Pathol Suppl (R Coll Pathol); 1980; 14():68-73. PubMed ID: 7000850
    [No Abstract]   [Full Text] [Related]  

  • 9. The fibrinolytic activity of cerebrospinal fluid after subarachnoid hemorrhage.
    Steinmetz H; Grote E
    Neurol Res; 1983; 5(4):59-65. PubMed ID: 6149487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation and fibrinolytic activity of cerebrospinal fluid.
    Anderson M; Matthews KB; Stuart J
    J Clin Pathol; 1978 May; 31(5):488-92. PubMed ID: 649775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifibrinolytic treatment in subarachnoid hemorrhage.
    Vermeulen M; Lindsay KW; Murray GD; Cheah F; Hijdra A; Muizelaar JP; Schannong M; Teasdale GM; van Crevel H; van Gijn J
    N Engl J Med; 1984 Aug; 311(7):432-7. PubMed ID: 6379455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting coagulation: fibrinolysis in chronic subdural fluid collections.
    Weir B; Gordon P
    J Neurosurg; 1983 Feb; 58(2):242-5. PubMed ID: 6848682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemostasis in cerebrospinal fluid. Basic concept of antifibrinolytic therapy of subarachnoid haemorrhage.
    Hindersin P; Heidrich R; Endler S
    Acta Neurochir Suppl (Wien); 1984; 34():1-77. PubMed ID: 6395643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolytic activity in blood and cerebrospinal fluid in subarachnoid hemorrhage from ruptured intracranial saccular aneurysm before and during EACA treatment.
    Filizzolo F; D'angelo V; Collice M; Ferrara M; Donati MB; Porta M
    Eur Neurol; 1978; 17(1):43-7. PubMed ID: 624294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative treatment of ruptured intracranial aneurysms with tranexamic acid and monitoring of fibrinolytic activity.
    Alvarez Garijo JA; Vilches JJ; Aznar JA
    J Neurosurg; 1980 Apr; 52(4):453-5. PubMed ID: 7373370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrinolytic activity of cerebrospinal fluid in subarachnoid hemorrhage (author's transl)].
    Imanaga H; Osugi T; Kagawa M; Kita-Mura K
    No Shinkei Geka; 1977 Jan; 5(1):51-8. PubMed ID: 557178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of cerebral vasospasm value of fibrinogen degradation products (FDP) in the cerebro-spinal fluid (CSF) for prediction of vasospasm following subarachnoid haemorrhage due to a ruptured aneurysm.
    Guggiari M; Dagreou F; Rivierez M; Mottet P; Gallais S; Philippon J; Viars P
    Acta Neurochir (Wien); 1984; 73(1-2):25-33. PubMed ID: 6496196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: a double-blind clinical trial.
    Chandra B
    Ann Neurol; 1978 Jun; 3(6):502-4. PubMed ID: 354483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: a double-blind controlled clinical trial.
    van Rossum J; Wintzen AR; Endtz LJ; Schoen JH; de Jonge H
    Ann Neurol; 1977 Sep; 2(3):238-42. PubMed ID: 365072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: a prospective randomized study.
    Hillman J; Fridriksson S; Nilsson O; Yu Z; Saveland H; Jakobsson KE
    J Neurosurg; 2002 Oct; 97(4):771-8. PubMed ID: 12405362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.